Cigarette smokers who try to quit often end up vaping and smoking

Industry Insight
Jul.22.2022

Most of the 40 million Americans who smoke cigarettes say they want to quit, and some move to e-cigarettes as a step toward quitting. However, a growing number of such people become dual nicotine users: They smoke traditional cigarettes and vape e-cigarettes, researchers at Washington University School of Medicine in St. Louis have found.

Cigarette smokers who try to quit often end up vaping and smoking

Rather than discontinuing their addiction, many end up substantially increasing the amount of nicotine they consume. The good news, the researchers found, is that smoking-cessation treatments approved by the Food and Drug Administration (FDA) that focus on nicotine replacement and counseling can help such dual users quit. In fact, such treatments seem to be effective in dual users as well as those who smoke traditional cigarettes exclusively.

 

The findings are available July 21 in the journal Thorax.

 

"We recommend FDA-approved treatment such as nicotine replacement, the drug varenicline and counseling for cigarette smokers," said senior investigator Li-Shiun Chen, MD, an associate professor of psychiatry. "But we know that a growing number of people are using both cigarettes and e-cigarettes. The good news is that tobacco treatment still can help these people stop smoking and defeat their nicotine addition."

 

In an average year, about 70% of those who smoke will make an attempt to quit. Another 20% say they want to smoke less. But only about 5% of those who don't receive any treatment, such as nicotine replacement therapy and counseling, quit successfully.

 

In this review of de-identified electronic health records of more than 110,000 smokers who were seen in outpatient clinics at Barnes-Jewish Hospital between 2018 and 2020, Chen and her colleagues found that the number of e-cigarette users tripled. Some apparently started vaping as a potential step to quitting, but many seemed to get stuck. Instead of quitting, they started vaping while also continuing to smoke traditional cigarettes.

 

A relatively small but growing percentage of the smokers who were studied became dual users during the course of the study. Some 0.8% reported dual use in the study's first year, but that number had grown to 2.3% when data collection had concluded. The authors noted that the actual number of dual users was likely higher.

 

The researchers found that about one in five (20.8%) of the dual users quit smoking within 12 months. That compared to a 16.8% quit rate among those who smoked only traditional cigarettes.

 

Treatment still seemed to be the key for dual users. When they received smoking-cessation treatment, almost one-third (29%) became nonsmokers 12 months later. About 17% of dual users who didn't get treatment were able to quit.

 

First author Brendan T. Heiden, MD, a surgical resident and cardiothoracic surgery research fellow, said that although quit rates were higher among dual users, about two-thirds remained smokers a year later, even after treatment. That, combined with the fact that little is known about the long-term health effects of e-cigarette use, means that he and Chen don't recommend that people who want to quit smoking should start vaping.

 

"The current scientific consensus is that using both cigarettes and e-cigarettes is bad for you," Heiden said. "Although current guidelines do not recommend vaping for smoking cessation, we did find that among the growing number of people who use both of these products, traditional FDA-approved tobacco treatment—such as nicotine-replacement therapy and behavioral support therapy—can help them quit."

 

The content excerpted or reproduced in this article comes from a third-party, and the copyright belongs to the original media and author. If any infringement is found, please contact us to delete it. Any entity or individual wishing to forward the information, please contact the author and refrain from forwarding directly from here.

 

Product | Philip Morris Launches TEREA Bold Red and Bold Black in Germany With Level-10 Tobacco Intensity at €8 per Pack
Product | Philip Morris Launches TEREA Bold Red and Bold Black in Germany With Level-10 Tobacco Intensity at €8 per Pack
Philip Morris International (PMI) introduced TEREA Bold Red and Bold Black heated tobacco sticks in Germany in October 2026, both carrying a brand-rated tobacco-flavor intensity of 10, the highest level in the country's TEREA portfolio. Bold Red features leather and warm woody notes, while Bold Black combines woody and subtle floral notes. Both are sold in 20-stick packs at €8, approximately 2.6% above standard TEREA products. Germany's TEREA range now includes 11 flavor variants, alongside a separate 26-stick XL format priced at €10. IQOS Germany announced the new products on October 12, followed by a phased retail rollout from late October and an IQOS Club campaign running through December.
product
Nov.02
Why Does JPMorgan Favor BAT Over Philip Morris Despite Forecasting Slower Growth of 3.9% Versus 6.2%?
Why Does JPMorgan Favor BAT Over Philip Morris Despite Forecasting Slower Growth of 3.9% Versus 6.2%?
JPMorgan resumed equity research coverage of British American Tobacco (BAT), Philip Morris International (PMI) and Imperial Brands in November 2026, assigning BAT an Overweight rating and the other two companies Neutral ratings. The bank forecasts like-for-like sales growth of 3.9% for BAT and 6.2% for PMI in 2027, but estimates the two companies will trade at approximately 11 times and 21 times 2027 earnings, respectively. JPMorgan cited BAT's improving position in US nicotine pouches and vaping products as a driver of its investment outlook. BAT reported a 220% constant-currency increase in US modern oral nicotine revenue in the first half of 2026, while PMI's ZYN US shipments returned to growth in the third quarter. Imperial expects NGPs to represent 4% to 5% of sales and has expanded its oral portfolio through acquisitions.
Capital Markets
Nov.12
DATA|UK Retail Research Group IGD Says Convenience Tobacco and Vape Sales Fell 10.6%, With 15.4% Market Share Versus Alcohol's 15.1%; Top Rank at Risk in 2027
DATA|UK Retail Research Group IGD Says Convenience Tobacco and Vape Sales Fell 10.6%, With 15.4% Market Share Versus Alcohol's 15.1%; Top Rank at Risk in 2027
Combined tobacco and vaping sales in UK convenience stores fell 10.6% year over year in the first half of 2026, making the category a major drag on channel performance, according to retail research organization IGD. Total convenience sales declined 1.2%, while sales excluding tobacco and vaping increased 0.7%. IGD's 2026 category-share figures show tobacco and vaping accounting for 15.4% of convenience sales, compared with 15.1% for alcohol. The organization forecasts alcohol could overtake tobacco and vaping as the largest category by sales value as early as 2027 if current trends continue. IGD expects the convenience market to increase from £48.6 billion in 2026 to £54.9 billion in 2031, a 2.5% compound annual growth rate, or 3.4% excluding tobacco and vaping.
DATA
Nov.11
Product | PMI Launches Three IQOS ILUMA i BEYOND Limited Editions in Japan, Retaining REMIX Pricing and Retail Channel Structure
Product | PMI Launches Three IQOS ILUMA i BEYOND Limited Editions in Japan, Retaining REMIX Pricing and Retail Channel Structure
Philip Morris Japan (PMJ) began launching three IQOS ILUMA i BEYOND limited-edition heated tobacco devices in Japan on November 18, 2026, covering PRIME, the standard ILUMA i and ONE. Suggested retail prices are ¥11,980, ¥7,980 and ¥4,980, respectively, matching the REMIX limited-edition collection introduced in June. BEYOND features blue finishes, translucent components and differentiated surface materials while retaining the existing IQOS ILUMA i device architecture. As with REMIX, all three models are available through official and specialist retail channels, while the subsequent convenience store rollout covers only the standard ILUMA i and ONE versions. The two collections share the same pricing tiers and retail distribution structure, with their principal differences in exterior design.
product
Nov.20
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Product | PMI Launches ZYN Melts in UK, Extending ZYN Beyond Nicotine Pouches Into Dissolvable Tablets
Philip Morris International (PMI) has launched ZYN Melts in the UK, introducing a fully dissolvable oral nicotine tablet format alongside the brand's existing nicotine pouches. The range includes Cool Mint and Peppermint, each offered at 1mg and 2mg of nicotine per tablet, creating four SKUs. Each can contains 20 tablets and is priced at £6.50 in the UK. Unlike ZYN nicotine pouches, Melts are placed between the upper lip and gum and dissolve completely during use.
News
Sep.29 by 2Firsts Perspectives
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10